MONTPELLIER, France, Feb. 02, 2016 -- MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing innovative surgical assistance robots, is pleased to announce continued commercial expansion with two new sales of its ROSA™ Brain robot in the U.S., to Brigham and Women’s Hospital and the University of Colorado Medical Center.
Brigham and Women's Hospital, located in Boston, Massachusetts, is one of America’s most prestigious hospital centers, and has been recognized as one of the 10 best American hospitals by U.S. News & World Report.
The University of Colorado Medical Center in Aurora, Colorado is a renowned institution, particularly for neurology and neurosurgery. In 2015, it was ranked as the best hospital in the state of Colorado by U.S. News & World Report.
Bertin Nahum, CEO and Founder of Medtech, commented, “We are delighted with the ongoing increase of ROSA™ robots sold in the U.S., which is a significant market for our Company. These sales to prestigious institutions demonstrate the growing interest in our ROSA™ technology and the important role it can play supporting leading neurosurgeons and their patients.”
About MEDTECH
Founded in 2002 by Bertin NAHUM and based in Montpellier, MEDTECH is a European specialist in the design, development and marketing of innovative robotic appliances to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive treatment.
In 2007, MEDTECH developed ROSA™, an innovative technological device devoted to brain surgery procedures. ROSA™ has been approved in Europe, the United States and Canada.
In 2013 MEDTECH received the “European Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In July 2014, MEDTECH obtained the CE marking for its new product ROSA™ Spine, a robotic- assistive device for minimally invasive surgery of the spine.
In October 2014, MEDTECH won the “Révélation” prize in the Mediterranean Deloitte Technology Fast 50 Awards.
In 2015 MEDTECH received the “2016 Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In November 2015, MEDTECH was honored by Deloitte In Extenso for its excellent performance in the Technology Fast 50 Mediterranean Awards, in the “listed company” category.
In January 2016, MEDTECH obtained the FDA clearance for its new product, ROSA™ Spine, a robotic-assistive device for minimally invasive surgery of the spine.
CONTACT MEDTECH Christophe Sibillin Chief Financial Officer Tel : +33 (0)4 67 10 77 40 INVESTORS Corinne Puissant Tel : +33 (0)1 53 67 36 77 [email protected] PRESS Alexandra Prisa (EU) Tel. : +33(0)1 53 67 36 90 [email protected] Joanna Zimmerman (US) Tel : +1 646-536-7006 [email protected]


TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
OpenAI Explores Massive Funding Round at $750 Billion Valuation
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 



